



# GARDASIL ACCESS PROGRAM

**In 2007, our company made a major commitment to helping improve access to GARDASIL® [human papillomavirus quadrivalent (Types 6, 11, 16, 18) vaccine, recombinant] in developing countries.**

Through the GARDASIL Access Program, we pledged to donate at least 3 million doses of GARDASIL for use in smaller-scale human papillomavirus (HPV) vaccination projects in eligible lowest-income countries around the world, to enable participating organizations and institutions in those countries to gain operational experience in designing and implementing HPV vaccination projects. The program received proposals from applicants to conduct smaller-scale HPV vaccination projects rather than nationwide programs. All applicants were required to secure formal endorsement from their respective ministries of health, and were encouraged to follow World Health Organization (WHO) recommendations and guidelines for HPV vaccination.

In 2012, Gavi, the Vaccine Alliance, a public-private partnership focused on increasing access to immunization in developing countries, opened the funding window for HPV vaccines—giving countries the opportunity to introduce the vaccine sustainably through a demonstration or national program.

In this context, and following consultation with a wide array of stakeholders, including WHO, Gavi, PATH (an international nonprofit organization), other public health organizations, select ministries of health and some GARDASIL Access Program participants, and Axios Healthcare Development (AHD), a U.S. nonprofit organization, we decided that the GARDASIL Access Program would no longer be awarding doses of GARDASIL to new projects. However, options for use of the remaining doses of GARDASIL are currently being explored. Importantly, commitments to already-awarded projects will continue to be honored.

2014 included the conclusion of eight projects in seven countries, including a two-year GARDASIL Access Program demonstration project in Zambia.

As of February 2015, seven countries (Cameroon, Ghana, Kenya, Mali, Tanzania, Uganda and Uzbekistan) that participated in the GARDASIL Access Program were among the first approved by Gavi for HPV programs using GARDASIL. In addition, Lesotho, which completed two HPV vaccination projects with the support of the GARDASIL Access Program, continues to conduct a national HPV vaccination program without support from Gavi.


By actively disseminating information from the operational experiences and the lessons learned by participants, the program is contributing to the public knowledge base on HPV vaccine access and child and adolescent immunization models in developing countries.

The program is managed by AHD with strategic guidance provided by the independent GARDASIL Access Program Advisory Board, made up of international public health experts. AHD administers the program in consultation with Advisory Board recommendations and coordinates delivery of donated vaccine to participants. Technical assistance is provided by Axios International, a public health consultancy specializing in developing and emerging countries.


# PERFORMANCE

## GARDASIL® ACCESS PROGRAM SUMMARY


Doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] donated to participating organizations/institutions



Market value of GARDASIL donated to participating organizations/institutions (US\$M)



Lowest-income countries reached by the GARDASIL Access Program (cumulative)



As of December 31, 2014:

- More than 1,330,000 doses of GARDASIL have been shipped to 26 grantees in support of their proposed HPV vaccination projects in 21 countries: Bhutan, Bolivia, Cambodia, Cameroon, Georgia, Ghana, Guyana, Haiti, Honduras, Kenya, Kiribati, Lesotho, Mali, Moldova, Mongolia, Nepal, Tanzania, Papua New Guinea, Uganda, Uzbekistan and Zambia.
- 29 HPV-vaccination projects have been completed in 18 countries: Bhutan, Bolivia (four projects), Cambodia (two projects), Cameroon, Ghana, Guyana, Haiti, Honduras (four projects), Kenya, Kiribati, Lesotho (three projects), Mali, Moldova, Nepal (three projects), Tanzania, Uganda, Uzbekistan, and Zambia.
- There are two ongoing HPV-vaccination projects in two countries: Georgia and Mongolia.
- Axios routinely interviews all GARDASIL Access Program participants and analyzes their formal progress reports to synthesize lessons learned from the program.
- Axios publishes newsletters periodically to update stakeholders on program progress.
- A second manuscript, "Evaluation of 21 HPV Vaccination Programs Implemented in 14 Lowest-Income Countries, 2009–2013," was published in June 2014.